{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:23:51Z","timestamp":1772033031370,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly recognized as a valuable adjunct to cytoreductive surgery (CRS) in the management of ovarian cancer with peritoneal dissemination. This comprehensive review synthesizes contemporary evidence on the efficacy, safety, and future directions of HIPEC across various clinical settings, including primary, interval, and recurrent disease. Landmark studies such as the OVHIPEC-1 trial have demonstrated significant survival benefits when HIPEC is integrated into interval cytoreductive surgery following neoadjuvant chemotherapy, with improvements in both progression-free and overall survival without increasing severe morbidity. Survival gains have also been observed in upfront settings, particularly in patients with stage III epithelial ovarian cancer. However, evidence in recurrent disease remains mixed, with some trials showing benefit and others showing no significant advantage. Critical to the success of HIPEC are optimal patient selection and surgical quality, with completeness of cytoreduction (CC0\/CC1), low peritoneal cancer index (PCI), and biological factors such as tumor microenvironment composition emerging as key prognostic indicators. Although HIPEC is associated with a higher incidence of grade 3\u20135 adverse events, particularly renal and gastrointestinal toxicities, these are generally manageable in experienced centers. Enhanced recovery protocols and careful perioperative management have further improved safety profiles. Emerging innovations include combination with normothermic intraperitoneal chemotherapy, integration of immunotherapy such as intraperitoneal nivolumab, use of paclitaxel-based regimens, and exploration of minimally invasive techniques. Future directions also involve molecular profiling, AI-driven patient selection, and synergy with targeted therapies like PARP inhibitors. Ongoing research is essential to refine protocols, standardize patient selection, and integrate HIPEC into evolving systemic treatment landscapes. In conclusion, HIPEC represents a major advancement in the multimodal treatment of advanced ovarian cancer, offering meaningful survival benefits when applied in selected patients by multidisciplinary teams.<\/jats:p>","DOI":"10.3389\/fonc.2025.1714997","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:00Z","timestamp":1768196340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hyperthermic intraperitoneal chemotherapy in ovarian cancer: a comprehensive review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2024.12.004","article-title":"Hyperthermic intraperitoneal chemotherapy in the management of ovarian, fallopian tube and peritoneal carcinomas","volume":"34","author":"Chalif","year":"2025","journal-title":"Surg Oncol Clin N Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.07.026","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"200","author":"Bogani","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110424","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials","volume":"51","author":"Guerra","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110378","article-title":"The role of hyperthermia on abdominal tissue concentrations of cisplatin during and after intraperitoneal chemotherapy - insights from a porcine model","volume":"51","author":"Harlev","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17269-x","article-title":"Evaluating the role of hyperthermic intraperitoneal chemotherapy in cytoreductive surgery for advanced-stage ovarian cancer","volume":"32","author":"Kohut","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-16979-6","article-title":"Cytoreductive surgery plus HIPEC in recurrent or newly diagnosed advanced epithelial ovarian cancer: a meta-analysis","volume":"32","author":"Taliento","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jso.28166","article-title":"Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of epithelial ovarian cancer: A GRADE approach for evidence evaluation and recommendation","volume":"132","author":"Brennan","year":"2025","journal-title":"J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02731-6","article-title":"Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)","volume":"131","author":"Aronson","year":"2024","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.15094","article-title":"Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage III epithelial ovarian cancer: Follow-up of long-term survival","volume":"104","author":"Lei","year":"2025","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: A randomized trial on survival evaluation (HORSE; MITO-18)","volume":"43","author":"Fagotti","year":"2025","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2517676","DOI":"10.1001\/jamanetworkopen.2025.17676","article-title":"Interval cytoreductive surgery and cisplatin- or paclitaxel-based HIPEC for advanced ovarian cancer","volume":"8","author":"Gonz\u00e1lez S\u00e1nchez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17432-4","article-title":"Intraperitoneal intraoperative chemotherapy in advanced ovarian cancer: rethinking the future beyond complete macroscopic resection","volume":"32","author":"Cascales-Campos","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132113","article-title":"Advancing treatment outcomes for peritoneal surface Malignancies in low- and middle-income countries: insights from the first multicenter study in north africa","volume":"17","author":"Souadka","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: A randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020048","article-title":"Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: A randomized phase III clinical trial (HIPECOVA)","volume":"31","author":"Villarejo Campos","year":"2024","journal-title":"Curr Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176094","article-title":"Cytoreductive surgery in ovarian cancer: should the new optimal threshold be 2.5 mm","volume":"14","author":"Grigorie","year":"2025","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1458019","article-title":"Pathological PCI as a prognostic marker of survival after neoadjuvant chemotherapy in patients undergoing interval cytoreduction with or without HIPEC in FIGO stage IIIC high grade serous ovarian cancer","volume":"14","author":"Sinukumar","year":"2024","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.tjog.2025.05.015","article-title":"KELIM score and BRCA status are unreliable to predict the completeness of cytoreduction during interval debulking surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancers","volume":"64","author":"Fan","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12957-025-03686-5","article-title":"Textbook outcome in ovarian cancer and its impact on survival: comparative study","volume":"23","author":"Carbonell-Morote","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/s41467-024-46358-w","article-title":"Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102154","article-title":"The modified 5-factor frailty index predicts postoperative outcomes in patients with ovarian cancer undergoing hyperthermic intraperitoneal chemotherapy","volume":"57","author":"Kelley","year":"2024","journal-title":"Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15042-0","article-title":"Expanding the use of HIPEC in ovarian cancer at time of interval debulking surgery to FIGO stage IV and after 6 cycles of neoadjuvant chemotherapy: A prospective analysis on perioperative and oncologic outcomes","volume":"31","author":"Ghirardi","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051782","article-title":"Morbidity and mortality outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer","volume":"14","author":"Kim","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-025-00286-y","article-title":"Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis","volume":"37","author":"Marzuqi","year":"2025","journal-title":"J Egypt Natl Canc Inst"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100010","article-title":"Feasibility and safety of hyperthermic intra-peritoneal chemotherapy in patients with ovarian cancer and chronic kidney disease","volume":"35","author":"Mueller","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bpobgyn.2021.06.004","article-title":"Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer","volume":"78","author":"Vos","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12957-025-03954-4","article-title":"Is the tail of the pancreas always tumor-infiltrated when macroscopically affected during cytoreductive surgery? A clinicopathological study and experience from a high-volume center","volume":"23","author":"Acs","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27896","article-title":"Delay in time to adjuvant chemotherapy and its impact on oncological outcomes in patients undergoing optimal cytoreductive surgery for advanced ovarian cancer: analysis of 1480 cases from the Indian HIPEC registry","volume":"130","author":"Sp","year":"2024","journal-title":"J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1515\/pp-2024-0017","article-title":"Optimizing patient recovery: prospective study evaluating compliance and clinical outcomes of enhanced recovery protocols in ovarian cancer following cytoreductive surgery with HIPEC","volume":"10","author":"Somashekhar","year":"2025","journal-title":"Pleura Peritoneum"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101536","article-title":"Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy","volume":"56","author":"Pandraklakis","year":"2024","journal-title":"A feasibility study. Gynecol Oncol Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15719-6","article-title":"Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC): cancer survivors\u2019 Perspective through in-depth interviews","volume":"31","author":"Falla-Zuniga","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e260742","DOI":"10.1136\/bcr-2024-260742","article-title":"Acute embolic infarcts of bilateral cerebellar lobes, cerebral peduncles, thalami and left parietal lobe cortex following HIPEC surgery","volume":"18","author":"Kumar","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.08.047","article-title":"Pressurized intraperitoneal cold atmospheric plasma as a novel therapeutic strategy for peritoneal metastatic carcinoma","author":"Min","year":"2025","journal-title":"J Adv Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121957","article-title":"Combined hyperthermic intraperitoneal chemotherapy and normothermic intraperitoneal chemotherapy long-term after interval cytoreduction in ovarian cancer: A phase I clinical trial (BICOV1)","volume":"17","author":"Gonz\u00e1lez-Gil","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.12.019","article-title":"Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial","volume":"181","author":"Wu","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0507","article-title":"Intraperitoneal nivolumab after debulking surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer: A phase I study with expansion cohort","volume":"30","author":"Corbaux","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/ans.19021","article-title":"A systematic review of minimally invasive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal Malignancy","volume":"94","author":"Cohen","year":"2024","journal-title":"ANZ J Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.107950","article-title":"Secondary cytoreductive surgery followed by olaparib tab lets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study","volume":"50","author":"Yang","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17518-z","article-title":"National guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal Malignancies: A worldwide systematic review and recommendations of strength analysis","volume":"32","author":"Tonello","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.09.034","article-title":"Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection","volume":"47","author":"Schullian","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2024.10.002","article-title":"Disparities and health care delivery for patients with peritoneal surface Malignancy","volume":"34","author":"Deeb","year":"2025","journal-title":"Surg Oncol Clin N Am"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-152","article-title":"Discrepancy between recommendations regarding hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer management: a narrative review","volume":"13","author":"Pi\u0105tek","year":"2024","journal-title":"Chin Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1714997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:02Z","timestamp":1768196342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1714997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1714997"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1714997","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1714997"}}